Authors
Latest:
McIver Explores Treatment of a Patient With RET-Mutated Medullary Thyroid CancerDuring a virtual Targeted Oncology Case-Based Roundtable event, Bryan McIver, MD, PhD, discussed the case of a 58-year-old patient with RET-mutant medullary thyroid cancer.
Latest:
Pluvicto Approval Launches Theranostics in Prostate CancerAshok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.
Latest:
Combination of Venetoclax and Hypomethylating Agents Show Efficacy in AMLDanielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.
Latest:
RAD-SG Trial Evaluates RADiation Therapy and Sacituzumab Govitecan in MIBCOmar Mian, MD, PhD, provides an overview of the RAD-SG trial of RADiation therapy given with sacituzumab govitecan for bladder preservation in patients with muscle-invasive bladder cancer, which is currently in progress.
Latest:
Germline Testing Outside the Guidelines: Can it Address Health Disparities?The completion of the Human Genome project has ushered in a new era in our understanding of cancer.
Latest:
Bhatt Recaps Trial of Ruxolitinib in Steroid Refractory Sclerotic cGVHDVijaya Raj Bhatt, MBBS, MS, discusses background and findings from a multicenter, phase 2 study of ruxolitinib for the treatment of patients with steroid refractory sclerotic chronic graft-versus-host disease.
Latest:
Investigating KRAS/TP53 Co-Alterations in Pancreatic CancerJashodeep Datta, MD, explains KRAS and TP53 co-alterations in patients with pancreatic cancer.
Latest:
Optimizing the Management of Melanoma: Future Directions in CareClosing out his discussion on the management of metastatic melanoma, expert oncologist Sajeve Thomas, MD, summarizes unmet needs and looks toward future evolutions in the treatment paradigm.
Latest:
Challenging Barriers to Community Oncology CareDipti Patel-Donnelly, MD, highlights challenges for physicians and patients when managing treatment of hematologic malignancies in the community setting.
Latest:
The Future of Neoadjuvant Immunotherapy in MIBCDr Terence Friedlander closes his discussion by highlighting ongoing clinicals in neoadjuvant MIBC treatment that excite him and speculates on how he would use immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant setting.
Latest:
Experts Compare Available Regimens for a Patient With Sarcomatoid FeaturesDuring a Targeted Oncology Case-Based Peer Perspective virtual event, Amir Mortazavi, MD andMoshe Ornstein, MD, MA discussed available treatment regimen for a patient with clear cell renal cell carcinoma and sarcomatoid features.
Latest:
HR+/HER2- Metastatic Breast Cancer: Future Directions in CareClosing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
Latest:
Adapting to Second-Line Restrictions of Niraparib in Ovarian CancerThe approved PARP inhibitor niraparib has been beneficial for patients with recurrent ovarian cancer, but new second-line restrictions for certain patients have led physicians to be more cautious when re-challenging these patients.
Latest:
Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLCThe panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.
Latest:
Advancing Myeloma Treatment With Blood-Based MRD TestingIn this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Latest:
JAK Inhibitors and Resistance in MyelofibrosisAnthony Hunter, MD, discusses JAK inhibitor resistance and optimal strategies for treatment of patients with myelofibrosis.
Latest:
Trastuzumab Deruxtecan Shows Clinical Activity in HER2+ Solid TumorsFunda Meric-Bernstam, MD, discusses the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-expressing solid tumors.
Latest:
NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKIExpert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.
Latest:
SHP2 Inhibitors Undergo Exploration in CombinationsMelissa Johnson, MD, discussed SHP2 inhibitors with Targeted Therapies in Oncology.
Latest:
ENDOLA Study Demonstrates Promise of Olaparib Triplet in Endometrial CancerAn olaparib triplet demonstrated efficacy in patients with recurrent advanced or metastatic endometrial cancer treated in the ENDOLA clinical trial.
Latest:
Key Takeaways From the RELIEVE Study of T-DXd in Real-World mBCPaolo Tarantino, MD, discusses what to know about the real-world findings from the RELIEVE study which were presented at the 2023 San Antonio Breast Cancer Symposium.
Latest:
Ovarian Cancer Awareness Month: Strides in Up-front and Maintenance TherapyGizelka David-West, MD, analyzes the most compelling changes in up-front treatment and maintenance therapy for Ovarian Cancer Awareness Month.
Latest:
Utilizing MRD Testing in the Myeloma SpaceGayathri Ravi, MD, discusses the role minimal residual disease plays in decision making and treating patients with hematologic malignancies.
Latest:
Exploring Ongoing Trials With 177Lu-PSMA-617 in Prostate CancerArun Azad, MBBS, PhD, discusses ongoing studies of lutetium-177-PSMA radionuclide in patients with prostate cancer.
Latest:
Identifying a Link Between Cervical Cancer and Social Determinants of HealthRates of cervical cancer across the United States vary due to social determinants of health.
